BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 28430601)

  • 1. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
    Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
    Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista.
    Shi W; Yan D; Zhao C; Xiao M; Wang Y; Ma H; Liu T; Qin H; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
    Biochem Biophys Res Commun; 2017 Sep; 491(1):159-165. PubMed ID: 28711499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
    Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
    Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
    Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
    Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
    Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
    J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
    Wu X; Cao Y; Xiao H; Li C; Lin J
    Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
    Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
    PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
    Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
    Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
    Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma.
    Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
    Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.
    Zhao C; Wang W; Yu W; Jou D; Wang Y; Ma H; Xiao H; Qin H; Zhang C; Lü J; Li S; Li C; Lin J; Lin L
    Oncotarget; 2016 Mar; 7(11):12917-26. PubMed ID: 26883202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE
    Luo P; Shi W; Wang Y; Ma H; Liu T; Yan D; Huo S; Guo J; Wang M; Li C; Lin J; Zhang C; Li S; Lv J; Lin L
    Life Sci; 2020 Nov; 261():118304. PubMed ID: 32828944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
    Chen X; Tian J; Su GH; Lin J
    Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer.
    Kim L; Park SA; Park H; Kim H; Heo TH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanosoma cruzi, the causative agent of Chagas disease, modulates interleukin-6-induced STAT3 phosphorylation via gp130 cleavage in different host cells.
    Ponce NE; Carrera-Silva EA; Pellegrini AV; Cazorla SI; Malchiodi EL; Lima AP; Gea S; Aoki MP
    Biochim Biophys Acta; 2013 Mar; 1832(3):485-94. PubMed ID: 23253440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing the selective estrogen receptor modulator
    Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
    EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
    Xu S; Grande F; Garofalo A; Neamati N
    Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
    Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
    J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.